Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
 1 a 20 de 272 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Leonardi S, Frigoli E, Rothenbühler M, Navarese E, Calabró P, Bellotti P, Briguori C, Ferlini M, Cortese B, Lupi A, Lerna S, Zavallonito-Parenti D, Espposito G, Tresoldi S, Zingarelli A, Rigattieri S, Palmieri C, Liso A, Abate F, Zimarino M, Comeglio M, Gabrielli G, Chieffo A, Brugaletta S, Mauro C, Van Mieghem NM, Heg D, Jüni P, Windecker S, Valgimigli M, for the MATRIX Investigators. Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ 2016;354:i4935. [Ref.ID 100794]
2. Cita con resumen
Valgimigli M, Frigoli E, Leonardi S, Rothenbühler M, Gagnor A, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de Cesare N, Rigattieri S, Zingarelli A, Tosi P, van 't Hof A, Boccuzzi G, Omerovic E, Sabaté M, Heg D, Jüni P, Vranckx P, for the MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997-1009. [Ref.ID 99531]
3. Cita con resumen
Shahzad A, Kemp I, Mars C, Wilson K, Roome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL, Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH, for the HEAT-PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58. [Ref.ID 98362]
4. Cita con resumen
Anónimo. Antithrombotic drugs. Med Lett Drugs Ther 2014;56:103-8. [Ref.ID 98343]
5.Tiene citas relacionadas
Anónimo. New oral anticoagulants for acute venous thromboembolism. JAMA 2014;311:731-2. [Ref.ID 97143]
6.Tiene citas relacionadas
Di Nisio M, Middeldorp S. Treatment of lower extremity superficial thrombophlebitis. JAMA 2014;311:729-30. [Ref.ID 97142]
7.Tiene citas relacionadas
Wells PS, Forgie MA, Rodger MA. Treatment of venous thromboembolism. JAMA 2014;311:717-28. [Ref.ID 97141]
8.Tiene citas relacionadas
Mehta SR. Balancing thrombotic events and bleeding in primary PCI. N Engl J Med 2013;369:2263-5. [Ref.ID 96613]
9.Tiene citas relacionadas Cita con resumen
Steg PG, van 't Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Berg JT, van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, dell' Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P, for the EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207-17. [Ref.ID 96610]
11.Tiene citas relacionadas Cita con resumen
Silvain J, Beygui F, Barthélémy O, Pollack C, Cohen M, Zeymer U, Huber K, Goldstein P, Cayla G, Collet J-P, Vicaut E, Montalescot G. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012;344:16. [Ref.ID 92381]
12.Tiene citas relacionadas
James S. Enoxaparin for anticoagulation in patients undergoing PCI. BMJ 2012;344:9. [Ref.ID 92379]
13. Cita con resumen
Kastrati A, Neumann F-J, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz K-L, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci DS, Schömig A, Berger PB, Mehilli J, for the ISAR-REACT 4 Trial Investigators. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011;365:1980-9. [Ref.ID 91655]
15. Cita con resumen
Merriman E, Tran H. Antiplatelet drugs, anticoagulants and elective surgery. Australian Prescriber 2011;34:139-43. [Ref.ID 91367]
16. Cita con resumen
The PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 2011;364:1305-14. [Ref.ID 90536]
18.Tiene citas relacionadas Cita con resumen
Sabatine MS, Antman EM, Widimsky P, Ebrahim IO, Kiss RG, Saaiman A, Polasek R, Contant CF, McCabe CH, Braunwald E. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): randomised, double-blind, active-controlled, phase 2 trial. Lancet 2009;374:787-95. [Ref.ID 86737]
19.Tiene citas relacionadas
Eikelboom JW, Weitz JI. Otamixaban in acute coronary syndromes. Lancet 2009;374:762-4. [Ref.ID 86735]
20.Tiene citas relacionadas Cita con resumen
Monreal M. Hacia una mejor prevención de la enfermedad tromboembólica. Med Clin (Barc) 2009;133:21-2. [Ref.ID 86073]
Seleccionar todas
 
 1 a 20 de 272 siguiente >>